But while the U.S. Food and Drug Administration has approved more than two dozen drugs targeting a range of male sexual matters, pharma has turned a cold shoulder to female dysfunction, despite the prevalence of conditions
like hypoactive sexual desire disorder, a chronic disinterest in sex estimated to affect 8 to 14 percent of American women ages 20 to 49.